253 related articles for article (PubMed ID: 36308849)
1. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: A systematic review and network meta-analysis.
O'Donnell JPM; Gasior SA; Davey MG; O'Malley E; Lowery AJ; McGarry J; O'Connell AM; Kerin MJ; McCarthy P
Eur J Radiol; 2022 Dec; 157():110561. PubMed ID: 36308849
[TBL] [Abstract][Full Text] [Related]
2. Radiomic signatures derived from multiparametric MRI for the pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer.
Bian T; Wu Z; Lin Q; Wang H; Ge Y; Duan S; Fu G; Cui C; Su X
Br J Radiol; 2020 Nov; 93(1115):20200287. PubMed ID: 32822542
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
4. A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients.
Liu S; Du S; Gao S; Teng Y; Jin F; Zhang L
BMC Cancer; 2023 Jan; 23(1):15. PubMed ID: 36604679
[TBL] [Abstract][Full Text] [Related]
5. A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer.
McAnena P; Moloney BM; Browne R; O'Halloran N; Walsh L; Walsh S; Sheppard D; Sweeney KJ; Kerin MJ; Lowery AJ
BMC Med Imaging; 2022 Dec; 22(1):225. PubMed ID: 36564734
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Multiparametric MRI Radiomics-Based Nomogram in Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Two-Center study.
Wang X; Hua H; Han J; Zhong X; Liu J; Chen J
Clin Breast Cancer; 2023 Aug; 23(6):e331-e344. PubMed ID: 37321954
[TBL] [Abstract][Full Text] [Related]
7. A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Li C; Lu N; He Z; Tan Y; Liu Y; Chen Y; Wu Z; Liu J; Ren W; Mao L; Yu Y; Xie C; Yao H
Ann Surg Oncol; 2022 Nov; 29(12):7685-7693. PubMed ID: 35773561
[TBL] [Abstract][Full Text] [Related]
8. A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.
Sutton EJ; Onishi N; Fehr DA; Dashevsky BZ; Sadinski M; Pinker K; Martinez DF; Brogi E; Braunstein L; Razavi P; El-Tamer M; Sacchini V; Deasy JO; Morris EA; Veeraraghavan H
Breast Cancer Res; 2020 May; 22(1):57. PubMed ID: 32466777
[TBL] [Abstract][Full Text] [Related]
9. Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI.
Zhou J; Lu J; Gao C; Zeng J; Zhou C; Lai X; Cai W; Xu M
BMC Cancer; 2020 Feb; 20(1):100. PubMed ID: 32024483
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy.
Xiong Q; Zhou X; Liu Z; Lei C; Yang C; Yang M; Zhang L; Zhu T; Zhuang X; Liang C; Liu Z; Tian J; Wang K
Clin Transl Oncol; 2020 Jan; 22(1):50-59. PubMed ID: 30977048
[TBL] [Abstract][Full Text] [Related]
11. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
15. Intra and peritumoral PET radiomics analysis to predict the pathological response in breast cancer patients receiving neoadjuvant chemotherapy.
Aksu A; Güç ZG; Küçüker KA; Alacacıoğlu A; Turgut B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500002. PubMed ID: 38527731
[TBL] [Abstract][Full Text] [Related]
16.
Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
[TBL] [Abstract][Full Text] [Related]
17. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
[TBL] [Abstract][Full Text] [Related]
18. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
[TBL] [Abstract][Full Text] [Related]
19. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
20. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
